Business Context and Reporting Period
Company: Inhibikase Therapeutics, Inc. (IKT)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Inhibikase is a clinical-stage pharmaceutical company developing IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension (PAH). The company is currently enrolling patients in its pivotal global Phase 3 clinical study, IMPROVE-PAH, across 16 countries. The company has no commercial revenue and relies on equity financing to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(16,380,840) | $(13,678,735) |
| Loss Per Share (Basic & Diluted) | $(0.10) | $(0.15) |
| Research & Development Expenses | $10,839,150 | $10,513,579 |
| Selling, General & Administrative Expenses | $7,376,123 | $5,249,291 |
| Cash, Cash Equivalents & Marketable Securities | $170,368,745 | $113,034,400 (Dec 31, 2025) |
| Accumulated Deficit | $(159,060,640) | $(108,099,346) |
| Net Cash Used in Operating Activities | $(12,059,722) | $(4,103,530) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $2.7 million (19.8%) compared to Q1 2025. This increase is primarily driven by higher operating expenses, partially offset by increased other income.
- Operating Expenses:
- R&D: Increased by $325,571 (3.1%). The Q1 2025 period included a one-time non-cash charge of $7.4 million for acquired in-process research and development (IPR&D) from the CorHepta acquisition, which did not recur in Q1 2026. Excluding this prior period charge, R&D costs increased due to ongoing PAH program development.
- SG&A: Increased by $2.1 million (40.5%), driven primarily by a $2.2 million increase in stock-based compensation expense and higher personnel costs.
- Contingent Consideration: The change in fair value of contingent consideration liability decreased by $791,510 (67.9%) to a gain of $373,354, compared to a gain of $1.2 million in the prior year. The liability was settled via stock issuance in February 2026 upon meeting a service milestone.
- Investing Activities: Net cash used in investing activities was $80.5 million in Q1 2026, primarily due to the purchase of $90.6 million in marketable securities, offset by $10.1 million in maturities. In contrast, Q1 2025 showed net cash provided by investing activities of $21.1 million.
- Financing Activities: The company raised $2.9 million in net proceeds from the issuance of common stock under its At-The-Market (ATM) sales agreement in Q1 2026. No financing proceeds were recorded in Q1 2025.
Guidance, Outlook, and Risks
- Clinical Progress: The company announced the enrollment of the first patient in the IMPROVE-PAH Phase 3 study in April 2026. The study is utilizing the FAST-EU initiative to accelerate approval in 12 European countries, with a total of 16 countries approved globally. An Orphan Drug Designation application was submitted to the FDA in April 2026.
- Liquidity Outlook: As of March 31, 2026, the company held approximately $170.4 million in cash, cash equivalents, and marketable securities. Management estimates this is sufficient to fund operations for at least the next 12 months. The company anticipates needing substantial additional funding in the future to complete development and commercialization.
- Contractual Commitments: Estimated remaining contractual commitments for CRO and CMO services total approximately $67.6 million ($58.4 million for CROs and $9.2 million for CMOs), expected to be incurred through 2030. This excludes $7.5 million in performance-based milestones which are not currently considered probable.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to secure regulatory approval, the need for additional capital on favorable terms, and the potential for dilution from future equity issuances. The company is subject to increased compliance costs as it no longer qualifies as an "emerging growth company" but remains a "smaller reporting company."
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $170.4 million cash balance against the $67.6 million in known contractual commitments and projected burn rate for the Phase 3 trial.
- Dilution Potential: Review the terms of outstanding warrants (Series A-1, Series B-1, and Pre-Funded Warrants) totaling over 162 million shares, which could significantly dilute existing shareholders upon exercise.
- Clinical Milestones: Monitor the enrollment rates and interim safety/efficacy readouts for the IMPROVE-PAH study, as these are critical for regulatory approval and potential warrant exercise triggers.
- Stock-Based Compensation: Note the significant increase in stock-based compensation ($5.6 million in Q1 2026 vs. $2.0 million in Q1 2025) and its impact on future expense projections.
- Contingent Consideration: Confirm the full settlement of the CorHepta contingent consideration liability and the absence of new contingent liabilities.